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Abstract
Objectives The aetiology of hyposalivation in haematopoietic
stem cell transplantation (HSCT) recipients is not fully under-
stood. This study examined the effects of treatment-related
aetiological factors, particularly medications, on stimulated
salivary flow in HSCT recipients.
Subjects and methods Adult HSCT recipients (N = 118, 66
males, 27 autologous and 91 allogeneic transplants) were ex-
amined. Stimulated whole salivary flow rates (SWSFR) were
measured before HSCT and at 6 and 12 months post-HSCT.
Linear regression models were used to analyse the associa-
tions of medications and transplant-related factors with
salivary flow rates, which were compared to salivary flow
rates of generally healthy controls (N = 247).
Results The SWSFR of recipients were lower pre-HSCT
(mean ± standard deviation, 0.88 ± 0.56 ml/min; P < 0.001),
6 months post-HSCT (0.84 ± 0.61; P < 0.001) and 12 months
post-HSCT (1.08 ± 0.67; P = 0.005) than the SWSFR
of controls (1.31 ± 0.65). In addition, hyposalivation
(<0.7 ml/min) was more frequent among HSCT recipients
pre-HSCT (P < 0.001), 6 months post-HSCT (P < 0.001) and
12 months post-HSCT (P = 0.01) than among controls. The
SWSFRwas observed to improve over time being significant-
ly higher 12 months post-HSCT compared to pre-HSCT
(P < 0.001). The observed decrease of salivary flow could
not be explained by the examined transplant-related factors
and medications.
Conclusions Decreased stimulated salivary flow rates could
not be explained by the examined factors alone; these findings
indicate that hyposalivation in HSCT recipients exhibits a
multifactorial aetiology.
Clinical relevance All HSCT recipients should be considered
to be at high risk of hyposalivation and consequent oral dis-
eases, and they should be treated accordingly.
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Introduction
During the preceding five decades, haematopoietic stem cell
transplantation (HSCT) has evolved to become the standard of
care for a broad range of disorders and malignancies of the
haematopoietic system [1]. This phenomenon can primarily
be attributed to the rapid development and improved success
rates of HSCT therapy [2]. Although the number of HSCT
survivors is increasing, this therapy remains associated with
serious and debilitating long-term side effects, such as graft-
versus-host disease (GvHD), organ dysfunction and second-
ary malignancies [3, 4].
There is increasing evidence that HSCT, which includes
high-dose chemotherapy either with or without total body ir-
radiation (TBI), can cause acute and long-term side effects in
the oral cavity that affect patients’ general well-being [5–10].
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Recent studies have particularly focussed on hyposalivation
(i.e., reduced salivary flow), which is commonly exhibited by
allogeneic HSCT recipients immediately and even de-
cades after HSCT [5–10]. We previously found that
the percentages of allogeneic HSCT recipients, who suffer
from hyposalivation, as assessed by stimulated whole salivary
secretion rates, were 56 % at 6 months post-HSCT, 31 % at
1 year post-HSCT and 26 % at 2 years post-HSCT [8].
Another study reported comparable salivary gland
hypofunction and xerostomia findings at 6 to 24 months
post-HSCT [9]. Furthermore, we have found that salivary
flow rates, tear flow rates and subjective sicca symptoms
(e.g. xerostomia, xerophthalmia and dry skin) were signifi-
cantly affected in extremely long-term survivors of allogeneic
HSCT (at a mean duration of 17.5 years after allogeneic
HSCT) [10]. Sicca symptoms are also associated with long-
lasting impairments in quality of life (QoL) [10].
Hyposalivation post-HSCT may be caused by disease; ex-
tremely potent antineoplastic therapies, including HSCT con-
ditioning regimens and comorbidities and their therapies.
Standard chemotherapy schemas and conditioning with or
without TBI can affect salivary glands [11, 12]. The manage-
ment of comorbidity in patients may require a wide repertoire
of medications, including opioids, immunosuppressive sub-
stances, and antimicrobials; certain of these medications may
contribute to hyposalivation [13, 14]. Furthermore, allogeneic
HSCT may be accompanied by GvHD, which can directly
compromise salivary gland function [5]. Hyposalivation is of
paramount interest because a dry mouth is subjectively
distressing and because saliva has several protective functions
in the mouth; moreover, hyposalivation promotes caries, peri-
odontal diseases and oral yeast infections [15, 16]. Therefore,
control of hyposalivation has significant impacts with respect
to preventing oral and dental morbidities and promoting the
general well-being of HSCT recipients.
We have previously demonstrated that female sex, TBI and
severe chronic GvHD (cGvHD) are associated with an in-
creased prevalence of hyposalivation among allogeneic HSCT
recipients [8, 10]. The current study examined the associations
of transplant-related factors and medications with stimulated
whole salivary flow rates (SWSFR) in autologous and alloge-
neic HSCT recipients. The hypothesis was that medications can
partially explain the reduced SWSFR in these patients.
Subjects and methods
This prospective longitudinal study was approved by the
Ethics Committee of Basel (Ethikkommission beider Basel
311/10), Switzerland and was performed in accordance with
the Declaration of Helsinki. A total of 118 HSCT recipients
with complete medical and dental records who were treated in
the Department of Haematology of the University Hospital
Basel, Switzerland, for haematological malignancies between
2002 and 2009 were included (Table 1). Patients who received
follow-up at other hospitals in Switzerland were excluded
from this study.
One experienced dentist (TW) performed dental examina-
tions of patients; the first examination occurred immediately
prior to HSCT. At this time, most patients had already been
treated for their underlying disease using previously described
standard chemotherapy schemas and had received condition-
ing chemotherapy either with or without TBI [8].
Myeloablative conditioning regimens administered immedi-
ately before transplantation included (1) cyclophosphamide +
TBI (12 Gy), with or without VP16 (etoposide), and (2) cy-
clophosphamide + busulfan or BEAM (BCNU (carmustine),
etoposide, Ara-C (cytarabine) and melphalan). Non-
myeloablative conditioning included cyclophosphamide
alone and reduced intensity regimens of fludarabine + TBI
(2 Gy), with or without thymoglobulin.
After HSCT, all patients were included in a prospective oral
disease prevention programme, and follow-up examinations
were performed 6 and 12 months after transplantation in 102
and 95 patients, respectively. The medications prescribed dur-
ing the examined period were obtained from medical records
and grouped according to the pharmacological action [17].
Anymedication prescribed during an examined 6-month inter-
val was considered to be used during the interval in question.
A population of healthy volunteers with no self-reported
intake of medications served as control subjects (n = 247).
These control subjects were recruited from the Swiss bone
marrow donor register, and informed consent was obtained
from each participant prior to the acquisition of salivary flow
measurements, which occurred from 2008 to 2010.
SWSFR were measured in HSCT recipients at each ap-
pointment, with appointments occurring pre-HSCT (after con-
ditioning chemotherapy with or without TBI) and 6 and
12 months post-HSCT. SWSFR of control group subjects
were measured once. SWSFR were determined as follows.
First, a commercially available, individually packed, neutral
piece of paraffin wax (0.9 g/wax; Orion Diagnostica, Espoo,
Finland) was chewed for 1 min while swallowing saliva. A
new piece of wax was then chewed for 5 min; during this time,
all generated saliva was collected in a graduated (ml) test tube
(Sarstedt, Nümbrecht, Germany) [14]. SWSFR (ml/min) was
determined by dividing the volume of the saliva sample by the
collection time (in min). An SWSFR of ≤0.7 ml/min was
regarded as hyposalivation [14]. Given subjects’ stress and
anxiety levels, no limitations on eating, drinking, smoking or
oral hygiene habits were imposed prior to salivary flow mea-
surements. SWSFR measurements were conducted between
8:00 AM and 4:00 PM.
The mean SWSFR of HSCT recipients were compared to
the mean SWSFR of healthy controls. The effects of time and
potential influencing factors on the SWSFR of HSCT
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recipients were analysed using a linear-mixed effects model.
SWSFR were the dependent variable. The independent vari-
ables were age, sex, time, history of cGvHD, graft type (au-
tologous or allogeneic), stem cell source (bone marrow or
peripheral blood), regimen intensity (myeloablative versus re-
duced), HLA matching (related, unrelated, fully matched or
mismatched), diagnosis, medication group and number of
drugs. Medication groups with <10 subjects (i.e. groups for
medications that were rarely prescribed) were excluded
from the analyses of this study. P < 0.05 was consid-
ered to be statistically significant. A professional bio-
statistician performed statistical analyses using R software,
version 2.15.1.
Results
HSCTrecipients (n = 118—66males, 52 females; mean age—
49.3 years; age range—22–74 years) and 247 controls (106
males, 141 females; mean age—43 years, age range—22–
74 years) were included in the study. Among the HSCT recip-
ients, 27 subjects received autologous HSCT and 91 subjects
received allogeneic HSCT. In total, 50 % (n = 59) of HSCT
recipients received TBI and 56 % (n = 66) of HSCT recipients
received a myeloablative conditioning regimen (Table 1).
The SWSFR of HSCT recipients were significantly lower
pre-HSCT (n = 118; mean SWSFR ± standard deviation (SD)
(ml/min), 0.88 ± 0.56; P < 0.001), 6 months post-HSCT
(n = 102; SWSFR, 0.84 ± 0.61; P < 0.001) and 12 months
post-HSCT (n = 95; SWSFR, 1.08 ± 0.67; P = 0.0052) than
the SWSFR of healthy controls (n = 247; SWSFR,
1.31 ± 0.65). Hyposalivation (SWSFR < 0.7 ml/min) was
significantly more frequent among HSCT recipients pre-
HSCT (hyposalivation, 42.3 %; P < 0.001), 6 months post-
HSCT (hyposalivation, 51.0 %; P < 0.001) and 12 months
post-HSCT (hyposalivation, 29.2 %; P = 0.01) than among
healthy controls (hyposalivation, 16 %).
The regression analysis revealed that female gender has
significantly lower levels of SWSFRs compared to male gen-
der (P = 0.005). In addition, SWSFRs tend to improve over
time and the flow rates were significantly higher 12 months
post-HSCT compared to pre-HSCT (P = 0.0005) (Table 2).
However, none of the examined transplant-related factors,
which included cGvHD, graft type (autologous or allogeneic),
myeloablative full intensity versus reduced intensity condi-
tioning, stem cell source (bone marrow or peripheral blood),
HLA matching and diagnosis were associated with altered
salivary flow in HSCT recipients (Table 2; data on stem cell
source, HLA matching and diagnosis not shown).
An average of four (SD, 1.7; range, 0–8) different medica-
tions were used concomitantly by HSCT recipients. In de-
scending order, the medications most commonly used by
HSCT recipients were antivirals; antifungals; antacids; anti-
neoplastics and immunosuppressants; antibacterials; cortico-
steroids; cardiovascular drugs, which were limited to antihy-
pertensives for the study population; antiemetics; anxiolytics
and antidepressants. Neither the number of medications
used by a recipient nor the examined pharmaceutical
groups were significantly associated with decreased
SWSFR. (Tables 2 and 3).
Table 1 Demographics, diagnoses and transplantation-related factors of HSCT recipients
Total
(n)
Female
(n)
Age
(mean)
Autologous
(n)
TBI*
(n)
Myeloablative
conditioning (%)
Identical sibling
donor (%)
Matched Unrel.
Donor (%)
cGvHD
(n)
All patients 118 52 49 27 59 56 51 13 60
Acute leukaemia 39 16 46 4 20 74 75 20 22
Acute myeloid leukaemia 23 11 52 3 7 74 70 13 12
Acute lymphoblastic
leukaemia
16 5 39 1 13 75 56 31 10
Chronic leukaemia 25 12 53 4 14 52 60 12 14
Chronic myeloid leukaemia 16 6 49 1 10 69 63 19 9
Chronic lymphoblastic
leukaemia
9 6 60 3 4 22 56 0 5
Lymphoma 16 5 46 7 7 44 44 6 9
Non-Hodgkin’s lymphoma 10 2 52 3 6 40 60 10 6
Hodgkin’s lymphoma 6 3 35 4 1 50 17 0 3
Multiple myeloma 42 15 60 10 4 29 29 0 4
Myelodysplastic/Proliferative 15 9 51 2 14 67 47 13 11
Myelodysplastic syndrome 8 5 57 1 6 50 50 25 3
Others 7 4 44 2 7 83 50 0 7
Bone marrow failure 4 4 36 0 1 75 50 25 3
* Total body irradiation
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Discussion
This study examined the associations of medications
and transplant-related factors with SWSFR in HSCT re-
cipients. Low SWSFR with a tendency towards im-
provement over time was observed in HSCT recipients
during the 12-month study period. This result is consis-
tent with the findings of our previous study [8].
However, in contrast to our hypothesis, none of the studied
transplantation-related factors or medications explained the
decreased SWSFR among HSCT recipients.
Consistent with our observations, several prior studies have
demonstrated that reduced salivary flow is common and persis-
tent among HSCT recipients [6, 8–11]. Nonetheless, the
aetiological factors of hyposalivation have received little re-
search attention. In their seminal study, Imanguli et al. [7]
analysed factors that could potentially contribute to salivary
gland dysfunction inHSCT recipients with cGVHD. In linewith
the results of the current study, these researchers found no asso-
ciations of demographics and transplantation-related factors in-
cluding age, intensity and type of the conditioning regimen, type
of donor, severity of oral mucosal cGVHD or time after diagno-
sis of cGVHD with salivary gland dysfunction. Additionally, a
recent study determined that in HSCT recipients, xerostomia
was not associated with time, GVHD or stem cell source [9].
Sicca symptoms including xerostomia and dry eyes are very
common in cGVHD patients. It has been show that salivary
gland involvement is a clinically distinct manifestation of
cGVHD [5, 7, 18]. In many of the studies focusing on GVHD
and sicca symptoms, only subjects with the condition have been
included without comparison to HSCT recipients without
GVHD. However, in the current study, we examined all HSCT
recipients with or without cGVHD and the effect of cGVHD on
salivary flow rate was negligible. In our previous study, apart
from severe cGVHD that was associated with xerostomia
(P = 0.03), a history of GVHD or the presence of GVHD at
present did not correlate with sicca symptoms nor with
hyposalivation among very long-term HSCT survivors [10].
Thus, our results suggest that hyposalivation is independent
and a common phenomenon after HSCT regardless of GVHD.
Table 2 Multiple regression analysis of the relationships of age,
gender, time, graft type, regimen, cGVHD and number of medications
with stimulated salivary flow
GMR* 95 % CI P value
Model 1
Age 1.00 0.99 to 1.01
Gender (female) 0.74 0.59 to 0.91 0.005
Time (6-months post-HSCT) 0.92 0.82 to 1.04 0.19
Time (12-months post-HSCT) 1.27 1.11 to 1.44 0.0005
Model 2; graft type
Model 1 + Autologous graft 1.02 0.78 to 1.33 0.88
Model 3; full intensity regimen
Model 1 + Full intensity regimen 0.84 0.61 to 1.16 0.28
Model 3; chronic graft-versus-host disease
Model 1 + cGVHD 1.07 0.92 to 1.24 0.40
Model 4; number of medications
Model 1 + Medications (<2 vs. >4) 0.92 0.75 to 1.13 0.42
Model 1 + Medications (2–4 vs. >4) 0.93 0.82 to 1.07 0.31
* Geometric mean ratio (GMR) of stimulated saliva flow rates
Table 3 Medications and stimulated whole saliva flow rates (SWSFR; ml/min) before HSCT and at 6 and 12 months post-HSCT
Pre-HSCT 6 months post-HSCT 12 months post-HSCT
n (M) SWSFR* SD n (M) SWSFR* SD n (M) SWSFR* SD
Antacids 104 (58) 0.9 0.6 89 (50) 0.8 0.6 67 (35) 1.1 0.7
Antibacterials 100 (54) 0.9 0.6 86 (48) 0.9 0.6 60 (30) 1.1 0.7
Antidepressants 16 (8) 0.8 0.6 11 (6) 0.6 0.4 na na na
Antiemetics 18 (11) 0.8 0.5 10 (3) 0.7 0.4 na na na
Antihypertensives 22 (12) 0.8 0.6 23 (12) 0.9 0.8 20 (12) 1.3 0.9
Antifungals 106 (58) 0.9 0.6 92 (52) 0.9 0.6 54 (27) 1.1 0.7
Antivirals 107 (57) 0.9 0.6 89 (49) 0.8 0.6 66 (32) 1.1 0.7
Anxiolytics 17 (7) 0.9 0.4 na na na na na na
Corticosteroids 58 (32) 0.9 0.5 63 (34) 0.8 0.6 45 (27) 1.3 0.7
Antineoplastics and
immunosuppressants
103 (59) 0.9 0.6 44 (25) 0.8 0.5 40 (20) 1.1 0.6
Other drugs 27 (14) 0.9 0.4 30 (16) 0.9 0.8 28 (15) 1.0 0.6
All P values > 0.05 (for users versus non-users of a medication)
na not applicable; less than 10 users of the pharmaceutical in question
* mean
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In contrast to prior reports, the present study exam-
ined not only allogeneic HSCT recipients but also au-
tologous HSCT recipients. Autologous and allogeneic
HSCT recipients suffered from equally reduced SWSFR.
This novel finding suggests that salivary flow reduction can-
not be caused solely by the immunological disadvan-
tages of allogeneic transplantation, such as GvHD.
Instead, similarities between the diseases treated by au-
tologous and allogeneic HSCT, including the medica-
tions used in both types of cases, may play significant
roles in the aetiology of hyposalivation.
No previous studies have focussed on medications as
a cause of hyposalivation in HSCT recipients, although
most medications, particularly in the context of
polypharmacy, are well-known causes of hyposalivation
[13, 14]. A wide range of medications is commonly
utilized during the course of HSCT. Standard chemo-
therapy schemas initially aimed against the underlying
disease are followed by high-dose conditioning regimens
with highly potent cytotoxic agents [2]. Co-morbidities
after grafting, such as GvHD and infections, are routine-
ly managed with a broad repertoire of medications, in-
cluding immunosuppressive substances, corticosteroids,
antimicrobials and opioids [19–21]. Anxiety and discomfort
related to patients’ treatments and diseases often require the
use of antidepressants and anxiolytics. Nearly, all of these
medications have potential adverse effects that include de-
creased salivary secretion and xerostomia [22]. Nonetheless,
the current study failed to demonstrate any associations be-
tween reduced SWSFR and medications.
Several factors could contribute to this somewhat unex-
pected result. First, baseline SWSFR levels were not measured
in healthy states prior to the initiation of antineoplastic treat-
ments. Thus, even prior to HSCT, the SWSFR of transplanta-
tion recipients was already likely to be lower than the SWSFR
of healthy controls. The therapeutic regimen that preceded the
first salivary flow measurements may have substantially af-
fected SWSFR and thereby concealed the xerogenic effects of
subsequent medications. Additionally, it is challenging to un-
ambiguously assess medications, particularly in the examined
population, which generally consisted of subjects who used
several concomitant medications. Medication use was deter-
mined from medical records, but these data cannot guarantee
that patients continuously used all of their prescribed medica-
tions. In addition, there is limited understanding of the long-
term effects of salivary gland dysfunction caused by
polypharmacy. Cytotoxic agents could be expected to cause
long-lasting damage to the secretory cells of salivary glands,
whereas diuretics may produce more transient effects.
However, in contrast to our expectations, the SWSFR of
HSCT recipients who used less than two medications and
HSCT recipients who used more than four different medica-
tions were equally low.
In this study, a well-established and reliable paraffin
gum-based method was used to measure SWSFR [14,
23]. Relative to other sialometric approaches such as
gland-derived suction-based techniques or imaging tech-
niques like sialography, the collection of stimulated
whole saliva conserves time, is uninvasive, inexpensive
and easy to repeat with high retest reliability. In this
way, a good overall picture of the function of all the
major salivary glands can be achieved in an easy nu-
meric form (ml/min), without causing excess stress to
severely ill patients. Stimulated saliva is particularly im-
portant during eating; in fact, discomfort related to
hyposalivation may contribute to the malnutrition that
is commonly observed among HSCT recipients. However, in
addition to stimulated saliva, studies have demonstrated that
also low levels of unstimulated saliva are common among
HSCT recipients correlating with poor QoL [7, 10]. Relative
to stimulated saliva, unstimulated saliva is likely to be a
better metric for assessing xerostomia because salivary
secretion is unstimulated during most of the day. This
limitation of the present study warrants further investi-
gation to compare the rationales for using stimulated
versus unstimulated salivary flow measurements to eval-
uate healthy subjects and medically compromised pa-
tients. Additionally, xerostomia was not assessed in this
study but warrabts further studies.
SWSFR measurements were one component of the rela-
tively comprehensive medical evaluations performed prior to
transplantation and at 6 and 12 months post-HSCT; such eval-
uations typically involve anxiety and fear regarding treatments
and diseases. The stressful nature of the salivary measurement
setting may have significantly contributed to the obser-
vations of reduced stimulated salivary flow among
HSCT recipients. In fact, the partial recovery of stimu-
lated salivary flow observed at 12 months post-HSCT
may be caused by a reduction in stress. Stimulated and
unstimulated salivary flow rates are easy and inexpen-
sive to measure; thus, HSCT recipients could assess
these rates in a stress-free manner at home. Using this
approach, measurements could be obtained at short time
intervals to allow for analyses of the effects of short-
term medication use on salivary flow rates.
In conclusion, autologous and allogeneic HSCT recip-
ients suffered from low stimulated whole saliva secre-
tion and hyposalivation during the 12-month study pe-
riod. Demographics, transplantation-related factors and
medications were not associated with low SWSFR.
These results indicate that hyposalivation among these
subjects is a multi-causal phenomenon that involves
several concurrent aetiological factors. At present, all
HSCT recipients should be considered to be at high risk
of hyposalivation and consequent oral diseases, and they
should be treated accordingly.
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